EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Development of Autologous Dendritic Cell Vaccine Therapeutics for Canine Mammary Cancer

Richard Curtis Bird

Genes · 2026

DOI: 10.3390/genes17070794 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2026. Verfasst von Richard Curtis Bird. Beteiligte Einrichtung: Department of Pathobiology, College of Veterinary Medicine, Scott-Ritchey Research Center, Auburn University Research Initiative in Cancer (AURIC), A…. Hauptthemen laut MEDLINE: Cancer Vaccines, Mammary Neoplasms, Animal, Dendritic Cells, Dog Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Canine mammary tumors have been investigated to determine the causes of malignancy and to promote the development of more effective therapies. The current standard of care, surgical resection where possible, often still results in recurrence of disease. Thus, there is an unmet need for better, more effective therapies that can suppress recurrence in canine patients. Because canine and human mammary cancers, particularly carcinomas and adenocarcinomas, share many similarities in genetic defects, etiology, natural history, and environment, canine mammary cancer cell lines have also been used as effective models of human disease. The genetics and immune response to canine mammary/breast cancers have been investigated to better understand this disease complex and to promote the development of more effective therapies designed to treat individual canine patients. As cancer is a heterogeneous disease, the potential to determine and possibly predict the mechanisms promoting neoplasia would allow the advancement of targeted therapeutic targets/strategies to combat cancer directly. These investigations have led to the development and evaluation of immunotherapies designed to elicit immune recognition of cancer and its suppression, thus improving survival. Hybrid dendritic-cell fusion vaccines and other autologous cancer vaccine formulations have proven effective in suppressing recurrence and extending survival in canine mammary cancer patients following surgical resection. Although current vaccines are somewhat impractical for direct application in veterinary clinics, reported success points the way toward the development of more practical vaccines designed to promote the treatment of canine mammary cancer. They also suggest a possible mechanism whereby removing a tumor from its microenvironment can promote antigenicity by removing local extracellular vesicle-mediated immunosuppression. This review provides a novel perspective on the potential of canine genetics to inform and promote more successful immunotherapies and their value as models of human disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesMammary Neoplasms, AnimalDendritic CellsDog DiseasesAnimalsDogsFemaleImmunotherapyHumans

Stichwörter der Autor:innen

cancer gene defectscaninecell vaccinedendritic cellmammary cancer

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Pathobiology, College of Veterinary Medicine, Scott-Ritchey Research Center, Auburn University Research Initiative in Cancer (AURIC), Auburn University, Auburn, AL 36849, USA.

Zitieren

APA

Bird, R. C. (2026). Development of Autologous Dendritic Cell Vaccine Therapeutics for Canine Mammary Cancer. Genes. https://doi.org/10.3390/genes17070794

Vancouver

Bird RC. Development of Autologous Dendritic Cell Vaccine Therapeutics for Canine Mammary Cancer. Genes. 2026. doi:10.3390/genes17070794

BibTeX
@article{Bird2026,
  author = {Bird, Richard Curtis},
  title = {Development of Autologous Dendritic Cell Vaccine Therapeutics for Canine Mammary Cancer},
  journal = {Genes},
  year = {2026},
  doi = {10.3390/genes17070794}
}
Kostenlos starten →